Literature DB >> 15534119

Antiproliferative effects of interferon-alphaCon1 on ovarian clear cell adenocarcinoma in vitro and in vivo.

Yumi Takemoto1, Hirohisa Yano, Seiya Momosaki, Sachiko Ogasawara, Naoyo Nishida, Sakiko Kojiro, Toshiharu Kamura, Masamichi Kojiro.   

Abstract

PURPOSE: We examined the antiproliferative effect of IFN-alphaCon1 and its mechanism on ovarian clear cell adenocarcinoma in vitro and in vivo. EXPERIMENTAL
DESIGN: (a) The effects of IFN-alphaCon1 on growth, morphology, cell cycle, and type I IFN-alpha receptor (IFNAR-2) expression were examined on two ovarian clear cell adenocarcinoma cell lines (KOC-5C and KOC-7C) in vitro. (b) KOC-5C or KOC-7C cells were transplanted into nude mice, and changes in tumor volume, tumor weight, apoptosis, necrosis, and microvessel density were investigated. The expression of angiogenesis factors was examined in the serum and the developed tumors.
RESULTS: Both cell lines expressed IFNAR-2 mRNA, but its protein was detected only in KOC-7C. In KOC-7C cells, antiproliferative effects were observed in a time- and dose-dependent manner and cell division was blocked at the S phase. The KOC-7C tumors showed decreases in tumor volume and weight; a decreasing tendency in basic fibroblast growth factor (bFGF), vascular endothelial growth factor, and interleukin (IL)-8 protein expression in the tumor; a significant decrease in bFGF and IL-8 protein expression in the serum, and of microvessel density; and significant increase in apoptosis and necrosis in the tumor. In the KOC-5C tumors, these in vitro and in vivo changes were not apparent, and the antiproliferative effects of IFN-alphaCon1 were not obvious.
CONCLUSIONS: IFN-alphaCon1 suppresses tumor proliferation by inducing apoptosis, blocking the cell cycle, and inhibiting tumor angiogenesis. Our findings show that the clinical efficacy of IFN-alphaCon1 can be predicted by examining IFNAR-2 expression on tumor cells, and the efficacy of IFN-alphaCon1 treatment can be evaluated by measuring serum bFGF and IL-8 levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15534119     DOI: 10.1158/1078-0432.CCR-04-0279

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

1.  Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.

Authors:  Seiji Mabuchi; Chiaki Kawase; Deborah A Altomare; Kenichirou Morishige; Masami Hayashi; Kenjiro Sawada; Kimihiko Ito; Yoshito Terai; Yukihiro Nishio; Andres J Klein-Szanto; Robert A Burger; Masahide Ohmichi; Joseph R Testa; Tadashi Kimura
Journal:  Mol Cancer Ther       Date:  2010-07-27       Impact factor: 6.261

2.  Effect of exogenous interferon and an interferon inducer on western equine encephalitis virus disease in a hamster model.

Authors:  Justin G Julander; Venkatraman Siddharthan; Lawrence M Blatt; Kristiina Schafer; Robert W Sidwell; John D Morrey
Journal:  Virology       Date:  2006-11-21       Impact factor: 3.616

3.  Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary.

Authors:  Takeshi Hisamatsu; Seiji Mabuchi; Yuri Matsumoto; Mahiru Kawano; Tomoyuki Sasano; Ryoko Takahashi; Kenjiro Sawada; Kimihiko Ito; Hirohisa Kurachi; Russell J Schilder; Joseph R Testa; Tadashi Kimura
Journal:  Mol Cancer Ther       Date:  2013-04-24       Impact factor: 6.261

4.  mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.

Authors:  Seiji Mabuchi; Chiaki Kawase; Deborah A Altomare; Kenichirou Morishige; Kenjiro Sawada; Masami Hayashi; Masahiko Tsujimoto; Mareo Yamoto; Andres J Klein-Szanto; Russell J Schilder; Masahide Ohmichi; Joseph R Testa; Tadashi Kimura
Journal:  Clin Cancer Res       Date:  2009-08-18       Impact factor: 12.531

5.  Host STAT2/type I interferon axis controls tumor growth.

Authors:  Chanyu Yue; Jun Xu; Marc Daryl Tan Estioko; Kevin P Kotredes; Yolanda Lopez-Otalora; Brendan A Hilliard; Darren P Baker; Stefania Gallucci; Ana M Gamero
Journal:  Int J Cancer       Date:  2014-06-17       Impact factor: 7.396

6.  Expression of an IRF-3 fusion protein and mouse estrogen receptor, inhibits hepatitis C viral replication in RIG-I-deficient Huh 7.5 cells.

Authors:  Luyu Yao; Xiaobo Yan; Huijia Dong; David R Nelson; Chen Liu; Xiaoyu Li
Journal:  Virol J       Date:  2011-09-21       Impact factor: 4.099

7.  Pegylated interferon-α2a inhibits proliferation of human liver cancer cells in vitro and in vivo.

Authors:  Hironori Kusano; Jun Akiba; Sachiko Ogasawara; Sakiko Sanada; Makiko Yasumoto; Masamichi Nakayama; Keiko Ueda; Kosuke Ueda; Takashi Kurita; Keita Todoroki; Yumi Umeno; Osamu Nakashima; Hirohisa Yano
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

8.  Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C.

Authors:  Bart Kolendowski; Yudith Ramos Valdes; Hal Hirte; Hiroaki Itamochi; Wonjae Lee; Mark Carey; Trevor G Shepherd; Gabriel E DiMattia
Journal:  Cells       Date:  2020-11-03       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.